HOME >> BIOLOGY >> NEWS
Tufts Veterinary School scientists decode Cryptosporidium genome

NORTH GRAFTON, Mass., Oct. 28, 2004 - A team of scientists at Tufts University School of Veterinary Medicine has helped decode the genome sequence of Cryptosporidium hominis, an insidious parasite identified as one of the most common causes of waterborne diseases in humans and classified by the Centers for Disease Control and Prevention as a potential bioterrorist agent. The researchers' findings are reported in today's issue of the journal Nature.

Cryptosporidium hominis is a highly contagious parasite that lives in the intestines of infected humans. Since there are no effective treatments, it is a relentless public health concern.

"Sequencing the genome of Cryptosporidium will help us determine the underlying mechanisms of the organism's unusual resistance to antimicrobial agents, and enable us to develop preventive vaccines and/or pharmaceutical treatments," said Saul Tzipori, PhD, director of Tufts' Division of Infectious Diseases and a member of the multi-institutional team researching the genome.

Present in drinking and recreational water throughout the world, Cryptosporidium causes watery diarrhea that can lead to dehydration, weight loss, stomach cramps, fever, nausea, and vomiting. While healthy people usually overcome illnesses caused by the organism, it can be life threatening to malnourished children and people whose immune systems have been compromised because of cancer, AIDS, etc.

The Cryptosporidium pathogen, which can be found in the feces of both humans and animals, is difficult to work with, thereby impeding the efforts of investigators to conduct laboratory investigations and develop appropriate therapies.

Tufts researchers successfully isolated and propagated Cryptosporidium hominis in 2000, making Tufts the first research institution capable of propagating this pathogen.

In 2000, Tufts applied to the National Institutes of Health (NIH) for funding to enable a consortium o
'"/>

Contact: Barbara Donato
barbara.donato@tufts.edu
508-839-7910
Tufts University
28-Oct-2004


Page: 1 2

Related biology news :

1. Biologists at Tufts University discover 1 reason why chromosomes break, often leading to cancer
2. Tufts researchers are keeping track of vitamin K: Research summary
3. Friedman School of Nutrition Science and Policy at Tufts University...
4. Tufts David Walt named Howard Hughes Medical Institute Professor
5. Tufts expert examines the cardiovascular benefits of a Mediterranean-style diet
6. Tufts professor chews on the nutrition-oral health connection
7. The latest information coming from the Friedman School of Nutrition Science and Policy at Tufts University
8. Tufts nutrition scientists say it is premature to focus on nutrient supplements over diet
9. Tufts researchers shine light on firefly mysteries
10. Research notes: Policy points from the Friedman School of Nutrition Science and Policy at Tufts
11. Research news from the Friedman School of Nutrition Science and Policy at Tufts University

Post Your Comments:
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: